Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perseid Therapeutics LLC

Division of Astellas Pharma Inc.
www.perseidtherapeutics.com

Latest From Perseid Therapeutics LLC

“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas

After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.

“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas

After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.

BioPharmaceutical Japan

Asia On The Move: Personnel News From Roche, Astellas And Pfizer

China’s National Health and Family Planning Commission appoints eight deputy commissioners. Astellas hires a global head of pharmacovigilance from rival Takeda, while Chinese domestic drug makers lure executives away from multinational firms.

BioPharmaceutical China

Japan Pharma Annual Meeting Snapshot: Eisai, Dainippon, Shionogi, Ajinomoto, Astellas

The annual earnings meetings of Eisai, Dainippon Sumitomo, Shionogi, Ajinomoto and Astellas highlight critical issues impacting Japanese pharma, from the evolving domestic generics market, choosing whether to enter the biosimiliars fray and the impact of yen depreciation on reimbursement pricing.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • Grant Yonehiro, Pres. & CEO
  • Contact Info
  • Perseid Therapeutics LLC
    Phone: (650) 298-5800
    515 Galveston Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register